Do you hold palbociclib (or another CDK4/6 inhibitor) in a patient with metastatic HR+ breast cancer while receiving palliative radiation?
Do you hold palbociclib (or another CDK4/6 inhibitor) in a patient with metastatic HR+ breast cancer while receiving palliative radiation?
Join Mednetto vote and see how they answered.
Currently there are no large studies on combining radiation therapy with palbociclib. Many of the patients with hormone receptor positive metastatic breast cancer have bony metastases and often need radiation for palliation. There is a small study showing that combination of radiation and palbocicli...
Join for free or sign in to see the full answer
We run into this intermittently. Its a judgement call depending on how many areas to radiate, how long, how much prior therapy patient received, etc among other things. Often palliative radiation is short, so if in doubt just hold palbo.
Join for free or sign in to see the full answer
I agree with the comments above. The theoretical concern is that the cdk 4/6 inhibitor will put tumors cells into senescence and make radiation less effective, as has been shown in some preclinical models.While there is no clinical data yet confirming this, we have generally held cdk 4/6 inhibitors ...
Join for free or sign in to see the full answer
From a toxicity standpoint, I have treated a chest wall concurrently with palbociclib and Femara without any unusual toxicity.
Join for free or sign in to see the full answer